Abstract:The relationship of the neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with chemotherapy sensitivity and prognosis in lumina! B-like (human epidermal growth factor receptor 2-negative) breast cancer has not been well studied. The data from 980 patients were retrospectively collected for analysis. A low pretreatment platelet/lymphocyte ratio but not the neutrophil/lymphocyte ratio was associated with a greater pathologic complete responscomplete response of neoadjuvant chemotherapy and better disease-free survival in the present cohort study. Background: The neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) have been associated with the prognosis in breast cancer (BC). The relationship of the NLR and PLR with chemotherapy sensitivity and prognosis in luminal B-like (human epidermal growth factor receptor 2-negative [HER2(-)]) BC are not well studied. Patients and Methods: The clinical data from 980 patients with luminal B-like (HER2(-)) BC from June 2012 to June 2016 were collected. The differences among the variables were calculated using the chi(2) test. The associations among the clinicopathologic factors, pretreatment NLR, pretreatment PLR, and disease-free survival (DFS) were analyzed using Kaplan-Meier curves and Cox analyses. Results: The median follow-up was 37 months (range, 5-77 months). For the 480 patients who had received neoadjuvant chemotherapy, low pretreatment PLR values were associated with higher pathologic complete response (pCR) rates compared with the high PLR group (15.8% for low vs. 9.2% for high PLR group; P = .027). Multivariate analyses showed that larger tumors, a greater number of lymph nodes involved, a high Ki-67 score, and a high PLR were independent prognostic factors of worse outcomes for the patients with luminal B-like (HER2(-)) BC. The risk of metastasis and/or recurrence was greater for the high PLR group than for the low PLR group (hazard ratio, 1.576; 95% confidence interval, 1.039-2.390; P = .032). The pretreatment NLR showed no such associations among this cohort of patients. Conclusions: The results of the present study have shown that the pretreatment PLR is superior to the NLR as a predictor of pCR and DFS outcomes in patients with luminal B-like (HER2(-)) BC. A low pretreatment PLR was associated with higher pCR rates after neoadjuvant chemotherapy and was an independent predictive factor for better DFS outcomes among patients with luminal B-like (HER2(-)) BC. (C) 2020 Elsevier Inc. All rights reserved.

Platelet-to-lymphocyte, Neutrophil-to-lymphocyte and Lymphocyte-to-monocyte Ratios Are Related to Cancer-Related Fatigue and Quality of Life in Patients with Cancer: a Cross-Sectional Study.

Neutrophil–lymphocyte Ratio and Platelet–lymphocyte Ratio As Potential Predictive Markers of Treatment Response in Cancer Patients Treated with Immune Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer.

Usefulness of Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Hormone-Receptor-negative Breast Cancer.

Neutrophil-lymphocyte Ratio and Platelet-Lymphocyte Ratio Associations with Heart and Body Dose and Their Effects on Patient Outcomes in Locally Advanced Non-Small Cell Lung Cancer Treated with Definitive Radiotherapy.

Lymphocyte-to-Monocyte Ratio is Associated with the Poor Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratios May Aid in Identifying Patients with Non-Small Cell Lung Cancer and Predicting Tumor-Node-Metastasis Stages

Clinical Application Values of Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Multiple Cancers

Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients.

Changes in Neutrophil/lymphocyte and Platelet/lymphocyte Ratios after Chemotherapy Correlate with Chemotherapy Response and Prediction of Prognosis in Patients with Unresectable Gastric Cancer

High Neutrophil-to-lymphocyte Ratios Confer Poor Prognoses in Patients with Small Cell Lung Cancer

Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios Predict Chemotherapy Outcomes and Prognosis in Patients with Colorectal Cancer and Synchronous Liver Metastasis

Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients

Platelet-lymphocyte ratio is an independent prognostic factor in patients with ALK-positive non-small-cell lung cancer.

Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer.

Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2<SUP>-</SUP>) Breast Cancer

The Prognostic Value of Peripheral Inflammatory Cell Ratios in Patients with Cervical Cancer After Radiotherapy

Associations of Three Differential White Blood Cell Counts, Platelet Counts, and Their Derived Inflammatory Indices with Cancer-Related Fatigue in Patients with Breast Cancer Undergoing Chemotherapy.

Peripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: Lymphocyte.

Low Lymphocyte-to-white Blood Cell Ratio and High Monocyte-to-white Blood Cell Ratio Predict Poor Prognosis in Gastric Cancer

Diagnostic role of the neutrophil‐to‐lymphocyte ratio and the platelet‐to‐lymphocyte ratio in breast cancer: A systematic review and meta‐analysis